United Therapeutics (UTHR) Income from Continuing Operations (2009 - 2026)

United Therapeutics has reported Income from Continuing Operations for 18 years, with the latest figure at 274900000.0 in Q1 2026.

• Quarterly Income from Continuing Operations fell 14.68% year-over-year to 274900000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1287400000.0 (up 6.34% YoY) and the FY2025 annual result came in at 1334700000.0, up 11.68% from the prior year.
• Income from Continuing Operations slipped to 274900000.0 in Q1 2026 per UTHR's latest filing, from 364300000.0 in the prior quarter.
• Over five years, Income from Continuing Operations peaked at 364300000.0 in Q4 2025 and troughed at 116000000.0 in Q2 2022.
• A 5-year average of 265694117.65 and a median of 274900000.0 in 2026 frame the typical range for Income from Continuing Operations.
• The widest YoY moves for Income from Continuing Operations: up 747.7% in 2022, down 32.79% in 2022.
• Over 5 years, Income from Continuing Operations stood at 132100000.0 in 2022, then surged by 64.35% to 217100000.0 in 2023, then surged by 38.78% to 301300000.0 in 2024, then advanced by 20.91% to 364300000.0 in 2025, then dropped by 24.54% to 274900000.0 in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered 274900000.0, 364300000.0, and 338700000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.